Stocks in focus today: Today i.e. on 17 March 2025, some shares (Stocks in News) are ready to show action. Due to positive trigger, these stocks can stay in the market in the market today. If you are looking for better shares in Intrade, then you can keep a stock in focus. In this list today, Patanjali Foods, Indusind Bank, Alkem Lab, Dr Reddy’s Lab, Tata Motors, Voltas, Zydus Lifescienes, Kec International, Shilpa Medicare, WELSPUN SPECIALTY SOLSTIONS, Gr Shares like infraprojects, Maharashtra seamless, brigade enterprises, tejas networks, kpit technologies, galaxy surfactants, NTC Industries, 3M India, International Conveyors, Spacejet.
Patanjali foods
Adar Poonawala -owned Sanoti Properties has decided to sell its insurance subsidiary company Magma General Insurance to sell their stake in Baba Ramdev’s Patanjali Ayurved and DS Group for Rs 4,500 crore. Patanjali Ayurved is one of the promoters of Patanjali Foods.
Zydus lifescienes
The company has got the final approval to create Eluksadoline Tablet from United States Food and Drug Administration (USFDA), which are available in 75 mg and 100 mg of strength. Alluksadine is a mu-opioid receptor agonist, which is given for treatment of irritable bowl syndrome with diarrhea (IBS-D) in adults.
Alkem laboratories
The US FDA inspected the Biorisarch Monitoring (BIMO) at the company’s Bioqueline Center in Taloja, Maharashtra during 10-13 March. At the end of the inspection, no Form 483 was released by the US FDA. In addition, the company’s subsidiary, Elkem Medtech, has signed a share gales and share subscription agreement with Bombay Ortho Industries to get a 100 per cent stake in Bombay Ortho.
Dr Reddy’s Lab
The pharma company has ordered a batch of levetercatm in the United States to return 0.75 % sodium chloride injection in the United States in the United States due to incorrect labeling on the infusion bag. According to the rescue statement, patients are likely to experience adverse events from the wrong label products.
Tata motors
The company announced its intention to appoint Deloite Hasscines and Sales LLP as a stachuari auditor, which would be effective from FY 2028, provided that all regulatable complaments are met. The current Statuery Auditor BSR & Company will continue to audit Tata Motors by FY 2027.
Voltas
The board has appointed KV Sridhar as the Chief Financial Officer of the company, which will be effective from April 1, 2025. Apart from this, the board has approved the transfer of foreign branches in Dubai and Abu Dhabi to the company’s subsidiary Universal MEP Contracting LLC, Dubai, UAE for Rs 45-70 crore.
Indusind bank
Regarding IndusInd Bank, the Reserve Bank of India said that the bank has enough capital and its financial situation remains satisfactory. According to the financial results of Q3Fy25, the bank has maintained a 16.46 per cent comfortable capital addicwegie ratio and a provision coverage ratio of 70.20 per cent. By 9 March, liquidity coverage ratio was 113 per cent against the 100 per cent regulatory requirement. Meanwhile, HDFC Mutual Fund won the bank’s 0.2 per cent stake on March 11, increasing its shareholding from 4.82 per cent to 5.02 per cent.
Shilpa Medicare
The United States Food and Drug Administration (USFDA) inspected Unit-2 of Shilpa Pharma LifeSians in Raichur during 10-14 March. The US FDA stopped inspection with zero observation. This is the second consecutive zero 483 inspection on this site. Shilpa Pharma is a full -fledged subsidiary of Lifestyle Shilpa Medicare.
